Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
10%
Ph phase_1
7
70%
Ph phase_2
2
20%

Phase Distribution

7

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
7(70.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(10)

Detailed Status

Completed10

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (70.0%)
Phase 22 (20.0%)
Phase 31 (10.0%)

Trials by Status

completed10100%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

NCT01332656
completedphase_2

Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer

NCT01263886
completedphase_3

A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies

NCT00699517
completedphase_1

A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

NCT01293630
completedphase_1

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

NCT01193595
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT01332656Phase 2

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

Completed
NCT01263886Phase 2

Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer

Completed
NCT00699517Phase 3

A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies

Completed
NCT01293630Phase 1

A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

Completed
NCT01193595Phase 1

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

Completed
NCT00968916Phase 1

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors

Completed
NCT01095302Phase 1

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

Completed
NCT00719524Phase 1

AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor

Completed
NCT01063946Phase 1

A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor

Completed
NCT01021150Phase 1

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10